

Pistoia Alliance partners with Matador to enable pharma R&D in Japan

20 June 2023 | News

To unlock Japan's R&D expertise on areas including targeted immunotherapy, the human microbiome, and neurology

The Pistoia Alliance, a global, not-for-profit alliance that advocates for greater collaboration in life sciences R&D, has announced a new partnership with Matador Japan KK, experts in the Japanese pharmaceutical sector, to enable pre-competitive collaboration in the Japanese market.

The Alliance and Matador share the vision that bringing together experts from diverse backgrounds and experiences will enable companies to deploy new technologies and solve common R&D challenges faster and more effectively. By joining forces, the Alliance and Matador will help members accelerate research and grant them access to a truly global pharmaceutical ecosystem.

The formal partnership builds on a series of Japan-based events held by the Pistoia Alliance last year, where Matador CEO John Bolger discussed specific examples of how the Alliance's pre-competitive collaboration model of shared-risk and shared-reward delivers value. Together, the Alliance and Matador will create further networking and interest groups in the Japanese language and time-zone that directly benefit member organizations in the region.

Japanese pharmaceutical companies have demonstrated R&D excellence in areas such as targeted immunotherapy, the human microbiome, and neurology, and partnering with the Pistoia Alliance will give members access to global expertise in these domains.